Treating shR2 tumor-bearing mice with the FGFR inhibitor PD173074 reversed the increase in proliferation and angiogenesis to the level of control shLacZ tumors, suggesting that high FGFR1 signaling in shR2 tumors plays a crucial role in all of these responses. This evidence concerns the gene FGFR1 and neoplasm.